CliffBio
small molecule

VILTEPSO

VILTOLARSEN

Loss of exclusivityApril 2034latest FDA-listed patent expiry
CompanyNippon Shinyaku →See this company's full patent-cliff portfolio

Drug detail

Brand nameVILTEPSO
Active ingredientVILTOLARSEN
Strength250MG/5ML (50MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2020
Marketing statusRX

Listed patents

PatentExpiresType
9079934April 2034substance, product
10870676August 2031substance, product

Regulatory exclusivity

CodeExpires
ODE-280August 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VILTEPSO patent cliff — loss of exclusivity April 2034 | CliffBio